Journal
VACCINE
Volume 31, Issue 51, Pages 6092-6096Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2013.09.045
Keywords
Chikungunya virus; Vaccine; Virus-like particle; AG129; Subunits; El; E2
Categories
Funding
- Dutch Top Institute Pharma, project Development of recombinant live and subunit vaccines against chikungunya virus infections [T4-301]
Ask authors/readers for more resources
Chikungunya virus (CHIKV) causes acute illness characterized by fever and long-lasting arthritic symptoms. The need for a safe and effective vaccine against CHM/infections is on the rise due to on-going vector spread and increasing severity of clinical complications. Here we report the results of a comparative vaccination-challenge experiment in mice using three different vaccine candidates produced in insect cells by recombinant baculoviruses: (i) secreted (s)E1 and (ii) sE2 CHIKV glycoprotein subunits (2 mu g/immunization), and (iii) CHIKV virus-like particles (VLPs) (1 mu g E2 equivalent/immunization). These experiments show that vaccination with two subsequent administrations of 1 mu g of Matrix M adjuvanted CHIN VLPs completely protected AG129 mice from lethal CHIN challenge. Vaccination with El and E2 subunits provided partial protection, with half of the mice surviving but with significantly lower neutralizing antibody titres as compared to the VLP vaccinated mice. This study provides evidence that even a modest neutralizing antibody response is sufficient to protect mice from CHM/infections. Neutralization was the prominent correlate of protection. In addition, CHIKV VLPs provide a superior immune response and protection against CHIICV-induced disease in mice as compared to individual CHIKV-sEl and -sE2 subunits. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available